Thymosin β4 promotes autophagy and repair via HIF-1α stabilization in chronic granulomatous disease.
Giorgia RengaVasilis OikonomouSilvia MorettiClaudia StincardiniMarina M BelletMarilena ParianoAndrea BartoliStefano BrancorsiniPaolo MosciAndrea FinocchiPaolo RossiClaudio CostantiniEnrico GaraciAllan L GoldsteinLuigina RomaniPublished in: Life science alliance (2019)
Chronic granulomatous disease (CGD) is a genetic disorder of the NADPH oxidase characterized by increased susceptibility to infections and hyperinflammation associated with defective autophagy and increased inflammasome activation. Herein, we demonstrate that thymosin β4 (Tβ4), a g-actin sequestering peptide with multiple and diverse intracellular and extracellular activities affecting inflammation, wound healing, fibrosis, and tissue regeneration, promoted in human and murine cells noncanonical autophagy, a form of autophagy associated with phagocytosis and limited inflammation via the death-associated protein kinase 1. We further show that the hypoxia inducible factor-1 (HIF-1)α was underexpressed in CGD but normalized by Tβ4 to promote autophagy and up-regulate genes involved in mucosal barrier protection. Accordingly, inflammation and granuloma formation were impaired and survival increased in CGD mice with colitis or aspergillosis upon Tβ4 treatment or HIF-1α stabilization. Thus, the promotion of endogenous pathways of inflammation resolution through HIF-1α stabilization is druggable in CGD by Tβ4.
Keyphrases
- oxidative stress
- cell death
- endoplasmic reticulum stress
- induced apoptosis
- endothelial cells
- signaling pathway
- wound healing
- cell cycle arrest
- protein kinase
- type diabetes
- rheumatoid arthritis
- gene expression
- copy number
- high fat diet induced
- combination therapy
- single molecule
- systemic sclerosis
- induced pluripotent stem cells